IOBT News and Press, IO Biotech Inc. From 03/31/22

IO Biotech press release (NASDAQ:IOBT): FY Net loss was $67.9 million for the year ended December 31, 2021 compared to $12.0 million for the prior year period. Cash and cash equivalents of $211.5 million at December 31, 2021; cash runway sufficient to support operations through multiple data ...

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April-- -- Began Patient Recruitment for Global Phase 3 Combination Trial with Lead Asset IO102-IO103 and KEYTR...

Clinical Update from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma from New Data Cut as of December 1, 2021 Multiple Subgroup Analyses Will be Presented for the First Time, Including in Poor Prognosis Patients NEW YORK, March 08, 2022 ...

Gainers: Houston American Energy HUSA +157%. Imperial Petroleum IMPP +95%. Indonesia Energy Corporation INDO +74%. Camber Energy (NYSE:CEI) +49%. Nine Energy Service NINE +42%. Sunworks (NASDAQ:SUNW) +31%. Bed Bath & Beyond BBBY +28%. Eqonex EQOS +28%. Marine...

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today it will present at the 42nd Annual Cowen Health Car...

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors. M...

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win ® technology, today announced the publication of results from its Phase 1/2 MM1636 Melanoma trial...

IO Biotech (NASDAQ:IOBT) has entered into a third clinical trial collaboration and supply agreement with Merck (NYSE:MRK), through a subsidiary. IOBT shares down 11.5% premarket at $9.65. The purpose of the collaboration is to evaluate the safety and efficacy of IO Biotech’s ...

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today that it has entered into a third clinical trial collabora...

Shares of IO Biotech (IOBT +31.7%), which has been on a roller coaster ride over the last week, are significantly higher today. Trading in the stock was already halted twice this morning due to extraordinary market activity. As of 1013a ET, volume is ~1.4M shares. That compares to a daily ave...